AB0023, a monoclonal antibody against human LOXL2 protein, showed efficacy in the bleomycin mouse model of lung fibrosis as well as in preclinical models of liver fibrosis and cardiac fibrosis.20 This evidence concerns the gene LOXL2 and pulmonary fibrosis.